S43

The Skinny Labels, Big Savings Act (S.43) was introduced in the Senate on January 9, 2025, by Senator Hickenlooper (D-CO) and cosponsored by Senators Welch (D-VT), Cotton (R-AR), and Collins (R-ME). The bill was read twice and referred to the Senate Committee on the Judiciary. An identical companion bill (HR6485) has been introduced in the House and referred to the House Judiciary Committee. Both bills are at the earliest legislative stage — no hearings, no markups, no floor votes. The bill has zero direct federal funding implications; its mechanism is entirely regulatory and legal, not fiscal. The legislation directly responds to the Supreme Court's 2021 decision in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., which held that generic manufacturers could face liability for induced patent infringement when marketing skinny-label generics — even though the FDA had approved the label carve-out. The bill amends 35 U.S.C. § 271 to explicitly list three actions that do not constitute infringement of a method-of-use patent: (1) submitting or seeking FDA approval for a skinny-label application; (2) promoting or commercially marketing the drug with the skinny-label labeling; (3) describing the product as a generic or therapeutically equivalent to the listed drug. The safe harbor applies only if the labeling, promotion, or marketing does not reference the patented condition of use identified by the patent owner. Structural Winners: Generic manufacturers. Teva ($TEVA) is the single largest beneficiary — it was the defendant in the GlaxoSmithKline case and faces the most skinny-label litigation exposure. Viatris ($VTRS) is the second-largest pure-play US generics manufacturer and has a broad skinny-label pipeline across respiratory, cardiovascular, and CNS drugs. Both companies' skinny-launch revenues have been suppressed by the legal uncertainty created by the 2021 decision. Structural Losers: Brand-name pharmaceutical companies with multi-use blockbuster patents — Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), and Amgen ($AMGN) — will face accelerated generic competition for drug indications no longer protected by their method-of-use patents. Real Market Data Context: The generic manufacturer rally reflects market anticipation. Teva ($35.38) has surged 13.36% in 7 days and 24.8% in 30 days, now trading near its 52-week high of $37.35. Viatris ($14.97) has gained 1.49% (7-day) and 15.51% (30-day), approaching its 52-week high of $16.47. In contrast, brand-name stocks have declined in the same period: PFE ($26.26, -1.54% 7-day, -5.44% 30-day), JNJ ($227.35, -1.43% 7-day, -6.24% 30-day), MRK ($110.95, -3.2% 7-day, -6.05% 30-day), AMGN ($338.02, -3.04% 7-day, -3.15% 30-day). The divergence is consistent with the market pricing in a favorable regulatory regime shift for generics. Timeline: Both S.43 and HR6485 are at square one. For the bill to become law, it must pass through committee hearings, markup, floor votes in both chambers, and Presidential signature. The 119th Congress runs through January 2027. With bipartisan cosponsorship (both Democratic and Republican senators) and identical companion bills in both chambers, the probability is moderate for eventual passage, but near-zero for near-term enactment. The early-stage status and absence of a CBO score or committee action suggest no imminent market-moving event. Investors should treat this as a medium-to-long-term regulatory catalyst, not a short-term trading signal.